Insulet Corporation (NASDAQ:PODD) Shares Sold by Beacon Investment Advisory Services Inc.

Beacon Investment Advisory Services Inc. cut its stake in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 19.2% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 121,891 shares of the medical instruments supplier's stock after selling 28,889 shares during the quarter. Insulet makes up approximately 1.5% of Beacon Investment Advisory Services Inc.'s holdings, making the stock its 18th biggest holding. Beacon Investment Advisory Services Inc. owned about 0.17% of Insulet worth $32,010,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Envestnet Portfolio Solutions Inc. grew its holdings in Insulet by 2.3% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 2,113 shares of the medical instruments supplier's stock worth $552,000 after acquiring an additional 48 shares in the last quarter. Quadrant Capital Group LLC boosted its stake in shares of Insulet by 4.9% during the fourth quarter. Quadrant Capital Group LLC now owns 1,092 shares of the medical instruments supplier's stock valued at $285,000 after purchasing an additional 51 shares in the last quarter. OLD National Bancorp IN boosted its stake in shares of Insulet by 6.7% during the first quarter. OLD National Bancorp IN now owns 880 shares of the medical instruments supplier's stock valued at $231,000 after purchasing an additional 55 shares in the last quarter. Syon Capital LLC increased its holdings in Insulet by 5.6% during the fourth quarter. Syon Capital LLC now owns 1,114 shares of the medical instruments supplier's stock valued at $291,000 after buying an additional 59 shares during the period. Finally, MassMutual Private Wealth & Trust FSB raised its stake in Insulet by 23.1% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 314 shares of the medical instruments supplier's stock worth $82,000 after buying an additional 59 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on PODD. Oppenheimer increased their target price on Insulet from $312.00 to $324.00 and gave the company an "outperform" rating in a research report on Friday, May 9th. The Goldman Sachs Group began coverage on Insulet in a research note on Friday, May 30th. They set a "buy" rating and a $380.00 price objective for the company. Wolfe Research upgraded Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 target price on the stock in a research note on Tuesday, May 13th. Sanford C. Bernstein reissued an "outperform" rating on shares of Insulet in a research report on Friday, May 16th. Finally, Wall Street Zen cut shares of Insulet from a "buy" rating to a "hold" rating in a report on Saturday, June 14th. Four analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $321.00.

Insider Buying and Selling

In other Insulet news, SVP John W. Kapples sold 5,278 shares of the firm's stock in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the completion of the transaction, the senior vice president directly owned 23,180 shares of the company's stock, valued at approximately $7,382,134.60. This trade represents a 18.55% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.39% of the stock is currently owned by corporate insiders.

Insulet Stock Performance

Shares of PODD traded down $0.09 during trading hours on Thursday, reaching $286.58. 672,078 shares of the company traded hands, compared to its average volume of 576,712. The company has a quick ratio of 3.63, a current ratio of 4.47 and a debt-to-equity ratio of 1.21. The business has a fifty day moving average price of $306.37 and a 200-day moving average price of $281.45. Insulet Corporation has a 12-month low of $173.00 and a 12-month high of $329.33. The stock has a market capitalization of $20.17 billion, a P/E ratio of 51.54, a P/E/G ratio of 2.56 and a beta of 1.35.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 EPS for the quarter, topping analysts' consensus estimates of $0.81 by $0.21. The company had revenue of $569.00 million during the quarter, compared to analysts' expectations of $543.20 million. Insulet had a return on equity of 22.25% and a net margin of 18.29%. The firm's revenue was up 28.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.73 EPS. Equities analysts anticipate that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.